Clinical MilestonesPositive results from ongoing trials could pave the way for GT-02287, with the Phase 2 study expected to commence in the second half of the year, marking a critical step in the drug's development.
Drug EfficacyGT-02287 has shown potential to be disease-modifying in Parkinson's disease, which could represent a significant advancement over current treatments that only target symptoms.
Financial HealthWith recent equity financing, the company's financial position is strengthened, extending its operational runway and supporting ongoing clinical trials.